A multivariate analysis confirmed the independent prognostic value of PFS reduction for stage 3 disease according to ISS classification (HR = 2.59), the use of therapy based on thalidomide or bortezomib only (instead of a combination of these two drugs; HR = 2.75), thrombocytopenia (HR = 2.54), low albumins (HR = 2.35), LDH (HR = 3.28), and t(11; 14) CCND1/IGH translocation (HR = 5.66). Here, ALB is linked to Thrombocytopenia.